nach oben

Acta Neurologica Belgica

Erschienen in:

03.08.2022 | Review article

An umbrella review of systematic reviews with meta-analysis on the role of vitamins in Parkinson’s disease

verfasst von: Sama Rahnemayan, Sasan Ghazanfar Ahari, Reza Rikhtegar, Sevda Riyahifar, Sarvin Sanaie

Erschienen in: Acta Neurologica Belgica | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

This umbrella review aimed to systematically review the available literature and assess the association of dietary intake or serum levels of different vitamins and the risk of PD, to help find out more efficient treatments for PD patients by replenishing the deficiency of vitamins.

Methods

Pubmed/Medline, Scopus, Google Scholar and hand searching bibliographies of retrieved articles in duplicate, were used to detect all relevant meta-analyses investigating the relationship between vitamins and PD. After study selection, data were extracted from previously published meta-analyses and pooled by Review Manager version 5.4 and CMA software version 2.2.064 to achieve effect sizes. Level of statistical significance was set at P ≤ 0.05.

Results

14 meta-analyses were included in the meta-review. Serum vitamin D and B12 levels were significantly lower in PD (SMD = −0.67 and SMD = −0.40 respectively). Homocysteine (Hcy) levels were significantly higher in PD patients (SMD = 1.26). Also the odds ratio for highest vs. lowest vitamin E intake was 0.73 which was significant. However, there was no significant difference between vitamin A, C and B6 intake or serum levels in PD vs. control groups.

Conclusion

Serum vitamin D and B12 levels were significantly lower in PD in comparison to healthy individuals, while Hcy level was significantly higher in PD patients. Also higher vitamin E intake was associated with significantly lower risk of development of PD in comparison to lower vitamin E intake. However, there was no significant difference between risk of PD and higher vitamin A, C and B6 intake or serum levels of folate.

Nur mit Berechtigung zugänglich

Jankovic J, Tan EK (2020) Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91:795–808. https://doi.org/10.1136/jnnp-2019-322338CrossRefPubMed

Stojkovska I, Wagner BM, Morrison BE (2015) Parkinson’s disease and enhanced inflammatory response. Exp Biol Med (Maywood) 240:1387–1395. https://doi.org/10.1177/1535370215576313CrossRefPubMed

Zhao X, Zhang M, Li C et al (2019) Benefits of vitamins in the treatment of Parkinson’s disease. Oxid Med Cell Longev 2019:9426867. https://doi.org/10.1155/2019/9426867CrossRefPubMedCentralPubMed

Toth C, Brown MS, Furtado S et al (2008) Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 23:1850–1859. https://doi.org/10.1002/mds.22137CrossRef

Toth C, Breithaupt K, Ge S et al (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 68:28–36. https://doi.org/10.1002/ana.22021CrossRefPubMed

Ceravolo R, Cossu G, Bandettini di Poggio M et al (2013) Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord Off J Mov Disord Soc 28:1391–1397. https://doi.org/10.1002/mds.25585CrossRef

Uncini A, Eleopra R, Onofrj M (2015) Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry 86:490–495. https://doi.org/10.1136/jnnp-2014-308586CrossRefPubMed

Study Quality Assessment Tools NIH. https://www.nhlbi.nih.gov/ health-topics/study-quality-assessment-tools.

Takeda A, Nyssen OP, Syed A et al (2014) Vitamin A and carotenoids and the risk of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology 42:25–38. https://doi.org/10.1159/000355849CrossRefPubMed

10.

Etminan M, Gill SS, Samii A (2005) Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol 4:362–365. https://doi.org/10.1016/S1474-4422(05)70097-1CrossRefPubMed

11.

Talebi S, Ghoreishy SM, Jayedi A et al (2022) Dietary antioxidants and risk of Parkinson’s disease: a systematic review and dose-response meta-analysis of observational studies. Adv Nutr (Bethesda, Md). https://doi.org/10.1093/advances/nmac001CrossRef

12.

Xie Y, Feng H, Peng S et al (2017) Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson’s disease: a meta-analysis. Neurosci Lett 636:190–195. https://doi.org/10.1016/j.neulet.2016.11.007CrossRefPubMed

13.

Setién-Suero E, Suárez-Pinilla M, Suárez-Pinilla P et al (2016) Homocysteine and cognition: a systematic review of 111 studies. Neurosci Biobehav Rev 69:280–298. https://doi.org/10.1016/j.neubiorev.2016.08.014CrossRefPubMed

14.

Dong B, Wu R (2020) Plasma homocysteine, folate and vitamin B12 levels in Parkinson’s disease in China: a meta-analysis. Clin Neurol Neurosurg 188:105587. https://doi.org/10.1016/j.clineuro.2019.105587CrossRefPubMed

15.

Shen L (2015) Associations between B vitamins and Parkinson’s disease. Nutrients 7:7197–7208. https://doi.org/10.3390/nu7095333CrossRefPubMedCentralPubMed

16.

Chang M, Kwak S, Kwak S (2021) Effect of dietary vitamins C and E on the risk of Parkinson’s disease: a meta-analysis. Clin Nutr. https://doi.org/10.1016/j.clnu.2021.05.011CrossRefPubMed

17.

Zhao Y, Sun Y, Ji H-F, Shen L (2013) Vitamin D levels in Alzheimer’s and Parkinson’s diseases: a meta-analysis. Nutrition (Burbank, Los Angeles County, Calif) 29:828–832. https://doi.org/10.1016/j.nut.2012.11.018CrossRefPubMed

18.

Lv Z, Qi H, Wang L et al (2014) Vitamin D status and Parkinson’s disease: a systematic review and meta-analysis. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 35:1723–1730. https://doi.org/10.1007/s10072-014-1821-6CrossRef

19.

Rimmelzwaan LM, van Schoor NM, Lips P et al (2016) Systematic review of the relationship between vitamin D and Parkinson’s disease. J Parkinson’s Dis 6:29–37. https://doi.org/10.3233/JPD-150615CrossRef

20.

Luo X, Ou R, Dutta R et al (2018) Association between serum vitamin D levels and Parkinson’s disease: a systematic review and meta-analysis. Front Neurol 9:909. https://doi.org/10.3389/fneur.2018.00909CrossRefPubMedCentralPubMed

21.

Z Zhou, R Zhou, Z Zhang, K Li 2019 The association between vitamin D status, vitamin D supplementation, sunlight exposure, and Parkinsons disease: a systematic review and meta-analysis Med Sci Monit Int Med J Exp Clin Res 25 666 674 https://doi.org/10.12659/MSM.912840

22.

Wei Z, Li X, Li X et al (2018) Oxidative Stress in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front Mol Neurosci 11:236. https://doi.org/10.3389/fnmol.2018.00236CrossRefPubMedCentralPubMed

23.

Sato Y, Honda Y, Iwamoto J et al (2005) Abnormal bone and calcium metabolism in immobilized Parkinson’s disease patients. Mov Disord Off J Mov Disord Soc 20:1598–1603. https://doi.org/10.1002/mds.20658CrossRef

24.

Evatt ML, Delong MR, Khazai N et al (2008) Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 65:1348–1352. https://doi.org/10.1001/archneur.65.10.1348CrossRefPubMedCentralPubMed

25.

Abou-Raya S, Helmii M, Abou-Raya A (2009) Bone and mineral metabolism in older adults with Parkinson’s disease. Age Ageing 38:675–680. https://doi.org/10.1093/ageing/afp137CrossRefPubMed

26.

Ding H, Dhima K, Lockhart KC et al (2013) Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology 81:1531–1537. https://doi.org/10.1212/WNL.0b013e3182a95818CrossRefPubMedCentralPubMed

27.

Wang L, Evatt ML, Maldonado LG et al (2015) Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord Off J Mov Disord Soc 30:560–566. https://doi.org/10.1002/mds.26117CrossRef

28.

van den Bos F, Speelman AD, van Nimwegen M et al (2013) Bone mineral density and vitamin D status in Parkinson’s disease patients. J Neurol 260:754–760. https://doi.org/10.1007/s00415-012-6697-xCrossRefPubMed

29.

Liu Y, Zhang B-S (2014) Serum 25-hydroxyvitamin D predicts severity in Parkinson’s disease patients. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 35:67–71. https://doi.org/10.1007/s10072-013-1539-xCrossRef

30.

Yoon JH, Park DK, Yong SW, Hong JM (2015) Vitamin D deficiency and its relationship with endothelial dysfunction in patients with early Parkinson’s disease. J Neural Transm (Vienna, Austria: 1996) 122:1685–1691. https://doi.org/10.1007/s00702-015-1452-yCrossRef

31.

Wang J, Yang D, Yu Y et al (2016) Vitamin D and sunlight exposure in newly-diagnosed Parkinson’s disease. Nutrients 8:142. https://doi.org/10.3390/nu8030142CrossRefPubMedCentralPubMed

32.

Ozturk EA, Gundogdu I, Tonuk B et al (2016) Bone mass and vitamin D levels in Parkinson’s disease: is there any difference between genders? J Phys Ther Sci 28:2204–2209. https://doi.org/10.1589/jpts.28.2204CrossRefPubMedCentralPubMed

33.

Beyazal MS, Kırbaş S, Tüfekçi A, et al (2015) The relationship of vitamin D with bone mineral density in Parkinson’s disease patients. Eur Geriatr Med 4935:1 YP –103. https://doi.org/10.1016/j.eurger.2015.08.002

34.

Sleeman I, Aspray T, Lawson R et al (2017) The role of vitamin D in disease progression in early Parkinson’s disease. J Parkinson’s Dis 7:669–675. https://doi.org/10.3233/JPD-171122CrossRef

35.

Meamar R, Maracy M, Chitsaz A et al (2013) Association between serum biochemical levels, related to bone metabolism and Parkinson’s disease. J Res Med Sci 18:S39-42PubMedCentralPubMed

36.

Knekt P, Kilkkinen A, Rissanen H et al (2010) Serum vitamin D and the risk of Parkinson disease. Arch Neurol 67:808–811. https://doi.org/10.1001/archneurol.2010.120CrossRefPubMedCentralPubMed

37.

Petersen MS, Bech S, Christiansen DH et al (2014) The role of vitamin D levels and vitamin D receptor polymorphism on Parkinson’s disease in the Faroe Islands. Neurosci Lett 561:74–79. https://doi.org/10.1016/j.neulet.2013.12.053CrossRefPubMed

38.

Chen H, Zhang SM, Schwarzschild MA et al (2004) Folate intake and risk of Parkinson’s disease. Am J Epidemiol 160:368–375. https://doi.org/10.1093/aje/kwh213CrossRefPubMed

39.

de Lau LML, Koudstaal PJ, Witteman JCM et al (2006) Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 67:315–318. https://doi.org/10.1212/01.wnl.0000225050.57553.6dCrossRefPubMed

40.

Murakami K, Miyake Y, Sasaki S et al (2010) Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson’s disease: a case-control study in Japan. Br J Nutr 104:757–764. https://doi.org/10.1017/S0007114510001005CrossRefPubMed

41.

Miller JW, Selhub J, Nadeau MR et al (2003) Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 60:1125–1129. https://doi.org/10.1212/01.wnl.0000055899.24594.8eCrossRefPubMed

42.

Triantafyllou NI, Nikolaou C, Boufidou F et al (2008) Folate and vitamin B12 levels in levodopa-treated Parkinson’s disease patients: their relationship to clinical manifestations, mood and cognition. Parkinsonism Relat Disord 14:321–325. https://doi.org/10.1016/j.parkreldis.2007.10.002CrossRefPubMed

43.

Yuan R-Y, Sheu J-J, Yu J-M et al (2009) Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson’s disease patients. J Neurol Sci 287:64–68. https://doi.org/10.1016/j.jns.2009.09.007CrossRefPubMed

44.

Religa D, Czyzewski K, Styczynska M et al (2006) Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson’s disease. Neurosci Lett 404:56–60. https://doi.org/10.1016/j.neulet.2006.05.040CrossRefPubMed

45.

Shin H-W, Sohn YH (2009) Hyperhomocysteinemia in patients with Parkinson’s disease and relationship to Vitamin B level. JMD 2:33–36. https://doi.org/10.14802/jmd.09008

46.

Białecka M, Kurzawski M, Roszmann A et al (2012) Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson’s disease. Pharmacogenet Genomics 22:716–724. https://doi.org/10.1097/FPC.0b013e32835693f7CrossRefPubMed

47.

Song I-U, Kim J-S, Park I-S et al (2013) Clinical significance of homocysteine (hcy) on dementia in Parkinson’s disease (PD). Arch Gerontol Geriatr 57:288–291. https://doi.org/10.1016/j.archger.2013.04.015CrossRefPubMed

48.

Zoccolella S, dell’Aquila C, Abruzzese G et al (2009) Hyperhomocysteinemia in levodopa-treated patients with Parkinson’s disease dementia. Mov Disord Off J Mov Disord Soc 24:1028–1033. https://doi.org/10.1002/mds.22511CrossRef

49.

Camicioli RM, Bouchard TP, Somerville MJ (2009) Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson’s disease patients. Mov Disord Off J Mov Disord Soc 24:176–182. https://doi.org/10.1002/mds.22227CrossRef

50.

Ozer F, Meral H, Hanoglu L et al (2006) Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 28:853–858. https://doi.org/10.1179/016164106X110445CrossRefPubMed

51.

Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J et al (2009) Homocysteine and cognitive impairment in Parkinson’s disease: a biochemical, neuroimaging, and genetic study. Mov Disord Off J Mov Disord Soc 24:1437–1444. https://doi.org/10.1002/mds.22522CrossRef

52.

Chen W-W, Cheng X, Zhang X et al (2015) The expression features of serum Cystatin C and homocysteine of Parkinson’s disease with mild cognitive dysfunction. Eur Rev Med Pharmacol Sci 19:2957–2963PubMed

53.

Sławek J, Roszmann A, Robowski P et al (2013) The impact of MRI white matter hyperintensities on dementia in Parkinson’s disease in relation to the homocysteine level and other vascular risk factors. Neurodegener Dis 12:1–12. https://doi.org/10.1159/000338610CrossRefPubMed

54.

NF Pan, M Ye (2014) Relationship between plasma homocysteine and Parkinson′ s disease with dementia. Jiangsu Med J 40: 2278–2280.

55.

Hughes KC, Gao X, Kim IY et al (2016) Intake of antioxidant vitamins and risk of Parkinson’s disease. Mov Disord Off J Mov Disord Soc 31:1909–1914. https://doi.org/10.1002/mds.26819CrossRef

56.

Ying AF, Khan S, Wu Y et al (2020) Dietary antioxidants and risk of Parkinson’s disease in the Singapore Chinese Health Study. Mov Disord Off J Mov Disord Soc 35:1765–1773. https://doi.org/10.1002/mds.28173CrossRef

57.

Miyake Y, Fukushima W, Tanaka K et al (2011) Dietary intake of antioxidant vitamins and risk of Parkinson’s disease: a case-control study in Japan. Eur J Neurol 18:106–113. https://doi.org/10.1111/j.1468-1331.2010.03088.xCrossRefPubMed

58.

Zhang SM, Hernán MA, Chen H et al (2002) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59:1161–1169. https://doi.org/10.1212/01.wnl.0000028688.75881.12CrossRefPubMed

59.

Scheider WL, Hershey LA, Vena JE et al (1997) Dietary antioxidants and other dietary factors in the etiology of Parkinson’s disease. Mov Disord Off J Mov Disord Soc 12:190–196. https://doi.org/10.1002/mds.870120209CrossRef

60.

Hellenbrand W, Boeing H, Robra BP et al (1996) Diet and Parkinson’s disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47:644–650. https://doi.org/10.1212/wnl.47.3.644CrossRefPubMed

61.

Powers KM, Smith-Weller T, Franklin GM et al (2003) Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60:1761–1766. https://doi.org/10.1212/01.wnl.0000068021.13945.7fCrossRefPubMed

62.

Johnson CC, Gorell JM, Rybicki BA et al (1999) Adult nutrient intake as a risk factor for Parkinson’s disease. Int J Epidemiol 28:1102–1109. https://doi.org/10.1093/ije/28.6.1102CrossRefPubMed

63.

Yang F, Wolk A, Håkansson N et al (2017) Dietary antioxidants and risk of Parkinson’s disease in two population-based cohorts. Mov Disord Off J Mov Disord Soc 32:1631–1636. https://doi.org/10.1002/mds.27120CrossRef

64.

Anderson C, Checkoway H, Franklin GM et al (1999) Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Mov Disord Off J Mov Disord Soc 14:21–27. https://doi.org/10.1002/1531-8257(199901)14:1%3c21::aid-mds1006%3e3.0.co;2-yCrossRef

65.

de Rijk MC, Breteler MM, den Breeijen JH et al (1997) Dietary antioxidants and Parkinson disease the Rotterdam Study. Arch Neurol 54:762–765. https://doi.org/10.1001/archneur.1997.00550180070015CrossRefPubMed

66.

Paganini-Hill A (2001) Risk factors for parkinson’s disease: the leisure world cohort study. Neuroepidemiology 20:118–124. https://doi.org/10.1159/000054770CrossRefPubMed

67.

Tan LC, Koh W-P, Yuan J-M et al (2008) Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. Am J Epidemiol 167:553–560. https://doi.org/10.1093/aje/kwm338CrossRefPubMed

68.

Morens DM, Grandinetti A, Waslien CI et al (1996) Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology 46:1270–1274. https://doi.org/10.1212/wnl.46.5.1270CrossRefPubMed

69.

Mrabet S, Ben Ali N, Achouri A et al (2016) Gastrointestinal dysfunction and neuropathologic correlations in Parkinson disease. J Clin Gastroenterol 50:e85-90. https://doi.org/10.1097/MCG.0000000000000606CrossRefPubMed

70.

Serrano-Urrea R, Garcia-Meseguer MJ (2013) Malnutrition in an elderly population without cognitive impairment living in nursing homes in Spain: study of prevalence using the Mini Nutritional Assessment test. Gerontology 59:490–498. https://doi.org/10.1159/000351763CrossRefPubMed

71.

Zhen D, Liu L, Guan C et al (2015) High prevalence of vitamin D deficiency among middle-aged and elderly individuals in northwestern China: its relationship to osteoporosis and lifestyle factors. Bone 71:1–6. https://doi.org/10.1016/j.bone.2014.09.024CrossRefPubMed

72.

Galesanu C, Mocanu V (2015) Vitamin D deficiency and the clinical consequences. Rev Med Chir Soc Med Nat Iasi 119:310–318PubMed

73.

Selhub J, Jacques PF, Wilson PW et al (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270:2693–2698. https://doi.org/10.1001/jama.1993.03510220049033CrossRefPubMed

74.

dos Santos EF, Busanello ENB, Miglioranza A et al (2009) Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson’s disease. Metab Brain Dis 24:257–269. https://doi.org/10.1007/s11011-009-9139-4CrossRefPubMed

75.

Ho PI, Collins SC, Dhitavat S et al (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 78:249–253. https://doi.org/10.1046/j.1471-4159.2001.00384.xCrossRefPubMed

76.

Mefford IN, Oke AF, Adams RN (1981) Regional distribution of ascorbate in human brain. Brain Res 212:223–226. https://doi.org/10.1016/0006-8993(81)90056-1CrossRefPubMed

77.

Grünewald RA (1993) Ascorbic acid in the brain. Brain Res Brain Res Rev 18:123–133. https://doi.org/10.1016/0165-0173(93)90010-wCrossRefPubMed

78.

Figueroa-Méndez R, Rivas-Arancibia S (2015) Vitamin C in health and disease: its role in the metabolism of cells and redox state in the brain. Front Physiol 6:397. https://doi.org/10.3389/fphys.2015.00397CrossRefPubMedCentralPubMed

79.

Kocot J, Luchowska-Kocot D, Kiełczykowska M et al (2017) Does vitamin C influence neurodegenerative diseases and psychiatric disorders? Nutrients. https://doi.org/10.3390/nu9070659CrossRefPubMedCentralPubMed

80.

Belluzzi E, Bisaglia M, Lazzarini E et al (2012) Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson’s disease. PLoS ONE 7:e38026. https://doi.org/10.1371/journal.pone.0038026CrossRefPubMedCentralPubMed

81.

Ide K, Yamada H, Umegaki K et al (2015) Lymphocyte vitamin C levels as potential biomarker for progression of Parkinson’s disease. Nutrition (Burbank, Los Angeles County, Calif) 31:406–408. https://doi.org/10.1016/j.nut.2014.08.001CrossRefPubMed

82.

Medeiros MS, Schumacher-Schuh A, Cardoso AM et al (2016) Iron and oxidative stress in Parkinson’s disease: an observational study of injury biomarkers. PLoS ONE 11:e0146129. https://doi.org/10.1371/journal.pone.0146129CrossRefPubMedCentralPubMed

83.

Atkinson J, Epand RF, Epand RM (2008) Tocopherols and tocotrienols in membranes: a critical review. Free Radical Biol Med 44:739–764. https://doi.org/10.1016/j.freeradbiomed.2007.11.010CrossRef

84.

Numakawa Y, Numakawa T, Matsumoto T et al (2006) Vitamin E protected cultured cortical neurons from oxidative stress-induced cell death through the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. J Neurochem 97:1191–1202. https://doi.org/10.1111/j.1471-4159.2006.03827.xCrossRefPubMed

85.

Borrelli E, Chambon P (1999) Control of transcription and neurological diseases. Mol Psychiatry 4:112–114CrossRefPubMed

Titel: An umbrella review of systematic reviews with meta-analysis on the role of vitamins in Parkinson’s disease
verfasst von: Sama Rahnemayan
Sasan Ghazanfar Ahari
Reza Rikhtegar
Sevda Riyahifar
Sarvin Sanaie
Publikationsdatum: 03.08.2022
Verlag: Springer International Publishing
Erschienen in: Acta Neurologica Belgica / Ausgabe 1/2023
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-022-02055-3

Role of the anterior choroidal artery in the endovascular treatment of brain arteriovenous malformations

Review article

Acute attack in a patient with multiple sclerosis 2 days after COVID vaccination: a case report

COVID-19
Letter to the Editor

D-dimer elevation after first alemtuzumab administration in a multiple sclerosis patient: case report

Letter to the Editor

A resting-state functional MRI study in patients with vestibular migraine during interictal period

Original article

Motor and non-motor features in Parkinson’s Disease patients carrying GBA gene mutations

Original Article

Paracoccidioidomycosis of the central nervous system with pulmonary involvement: typical imaging findings

Neuro-Images

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenz-Leitlinie aktualisiert

13.03.2025
Demenz
Nachrichten

Empfohlen wird jetzt auch eine Musiktherapie sowie bei unklarem diagnostischem Befund ein Tau-PET, und Depressive mit leichten kognitiven Störungen sollten eine Verhaltenstherapie erhalten – das sind einige wichtige Änderungen der aktuellen S3-Leitlinie Demenzen.

Frauen akkumulieren Tau-Protein schneller als Männer

13.03.2025
Morbus Alzheimer
Nachrichten

Frauen mit einer hohen Beta-Amyloid-Last im Gehirn aggregieren mehr Tau-Protein als Männer mit vergleichbaren Amyloidwerten. Ähnliches gilt für Frauen mit einem ApoE4-Allel. Dafür sprechen die Daten einer Metaanalyse von Menschen im präklinischen Alzheimerstadium.

Frauen mit Apoplex in Deutschland nicht benachteiligt – oder doch?

13.03.2025
Ischämischer Schlaganfall
Nachrichten

Eine Analyse von Daten des statistischen Bundesamtes spricht dafür, dass Frauen in der Schlaganfallbehandlung nicht benachteiligt sind. Im Detail bleiben aber Fragen offen.

MS-Medikamente absetzen: ab 60 Jahren eine Option

06.03.2025
Multiple Sklerose
Nachrichten

Wann können ältere MS-Kranke ihre krankheitsmodifizierende Therapie gefahrlos absetzen? Bisher lieferten kontrollierte Studien hier keine eindeutigen Antworten. Eine neue Auswertung der Studie DISCOMS deutet auf einen grenzwertigen Nutzen ab 60 Jahren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

An umbrella review of systematic reviews with meta-analysis on the role of vitamins in Parkinson’s disease

Abstract

Introduction

Methods

Results

Conclusion

Weitere Artikel der Ausgabe 1/2023

Role of the anterior choroidal artery in the endovascular treatment of brain arteriovenous malformations

Acute attack in a patient with multiple sclerosis 2 days after COVID vaccination: a case report

D-dimer elevation after first alemtuzumab administration in a multiple sclerosis patient: case report

A resting-state functional MRI study in patients with vestibular migraine during interictal period

Motor and non-motor features in Parkinson’s Disease patients carrying GBA gene mutations

Paracoccidioidomycosis of the central nervous system with pulmonary involvement: typical imaging findings

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Neu im Fachgebiet Neurologie

Demenz-Leitlinie aktualisiert

Frauen akkumulieren Tau-Protein schneller als Männer

Frauen mit Apoplex in Deutschland nicht benachteiligt – oder doch?

MS-Medikamente absetzen: ab 60 Jahren eine Option

Update Neurologie

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten